Form 4 for TRAW Traws Pharma, Inc.
Accepted 2024-04-03 00:00:00 ET · period of report 2024-04-01 · accession 0000929638-24-001364 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-04-03 | 2024-04-01 | TRAW | Pauza Charles David | CSO Virology | A - Grant | — | +97.5K | 97.5K | New | — |
| DM | 2024-04-03 | 2024-04-01 | TRAW | Pauza Charles David | CSO Virology | A - Grant | — | +836.4K | 333.1K | New | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-04-01 | A | A | 97,500 | — | 97,500 | D | — | — | (F1) Represents an award of restricted stock units that will vest in four equal annual installments beginning April 1, 2025. Each restricted stock unit will convert into shares of common stock of Traws Pharma, Inc. (f/k/a Onconova Therapeutics, Inc., the "Company"), par value $0.01 per share ("Common Stock"), on a one-for-one basis. |
| 2 | Derivative | Stock Option (right to purchase) | 2024-04-01 | A | A | 503,227 | — | 503,227 | D | $0.01 · 2023-11-01 to 2033-10-31 | 503,227 Common Stock | (F2) On April 1, 2024, the Company acquired Trawsfynydd Therapeutics, Inc. ("Trawsfynydd") in accordance with the terms of an Agreement and Plan of Merger, dated April 1, 2024 (the "Merger Agreement"), by and among the Company, Traws Merger Sub I, Inc., Traws Merger Sub II, LLC, and Trawsfynydd (the "Merger"). Upon consummation of the Merger, all of the outstanding shares of common stock of Trawsfynydd were converted into shares of Common Stock on a 1:20.1291 basis pursuant to the terms of the Merger Agreement. (F4) Received in the Merger in exchange for stock options to acquire 25,000 shares of Trawsfynydd common stock with an exercise price of $0.0001 per share. |
| 3 | Derivative | Stock Option (right to purchase) | 2024-04-01 | A | A | 333,136 | — | 333,136 | D | $0.07 · 2023-11-01 to 2033-10-31 | 333,136 Common Stock | (F2) On April 1, 2024, the Company acquired Trawsfynydd Therapeutics, Inc. ("Trawsfynydd") in accordance with the terms of an Agreement and Plan of Merger, dated April 1, 2024 (the "Merger Agreement"), by and among the Company, Traws Merger Sub I, Inc., Traws Merger Sub II, LLC, and Trawsfynydd (the "Merger"). Upon consummation of the Merger, all of the outstanding shares of common stock of Trawsfynydd were converted into shares of Common Stock on a 1:20.1291 basis pursuant to the terms of the Merger Agreement. (F3) Received in the Merger in exchange for stock options to acquire 16,550 shares of Trawsfynydd common stock with an exercise price of $1.38 per share. |